InnoGI Technologies collaborates with Simulations Plus to offer modeling solutions for prediction of oral drug performance

Delft, NetherlandsFriday, April 19, 2024, 15:00 Hrs  [IST]

Delft-headquartered an innovative CRO and technology provider for the pharmaceutical, InnoGI Technologies (formerly The TIM Company) has announced an exciting, market-driven collaboration with Simulations Plus Inc, to combine its TIM Technology, part of the InnoGI SurroGUT platform, with the GastroPlus and ADMET Predictor modelling software offered by Simulations Plus.

Understanding drug behavior following oral administration is important because solubility and absorption profiles affect dosing and efficacy. However, dynamic interactions between sparingly-soluble active pharmaceutical ingredients, excipients and the gastrointestinal environment are oversimplified in all static in vitro dissolution models and are very difficult to model using purely computational (in silico) approaches.

To address these challenges and reshape industry norms, we leverage our unique combination of advanced in vitro dynamic dissolution testing with the TIM Technology, accurately mimicking the physiological conditions of the human GI tract, and the GastroPlus and ADMET Predictor software to deliver cutting-edge predictive models.

Behzad Mahdavi, CEO of InnoGI Technologies, explains: "By leveraging the unique benefits of our SurroGUT platform combined with GastroPlus, we will generate cutting-edge predictive models and mechanistic in vitro–in vivo correlations (IVIVCs) that far outperform current approaches. This will improve the predictive accuracy of physiologically-based pharmacokinetic (PBPK) models, physiologically-based biopharmaceutics models (PBBMs), and facilitate the development of mechanistic IVIVCs."

GastroPlus is a sophisticated PBPM/PBBK modeling software platform that is renowned in the pharmaceutical, biotechnology, generics, chemicals, cosmetics and consumer goods industries for its precision and reliability. It is used by more than 200 companies, 350 universities, and 15 regulatory agencies worldwide, and has achieved significant academic and industrial recognition, being cited in more than 1500 peer-reviewed publications. This high level of adoption and citation is a testament to its utility in drug development and regulatory submission processes, providing robust, predictive models of drug and chemical behavior in virtual animals and humans.